Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Stopped The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.

Conditions

• Melanoma

Interventions

• DRUG: binimetinib
• DRUG: encorafenib

Sponsor

Pfizer

Collaborators

• [object Object]